Popular terms

Dimethyl topics
Physiologic
Hydrochloric Acid
Fresnel Zone
Aberration
Ophthalmic
Liquid Crystal
Imaging System
Pharmaceutically Acceptable Salt
Pharmaceutically Acceptable Salts
Chloric Acid
Tartaric Acid
Fumaric Acid
Antagonist
Bradykinin
Enantiomer

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Dimethyl patents



      

This page is updated frequently with new Dimethyl-related patent applications.




Date/App# patent app List of recent Dimethyl-related patents
06/23/16
20160177106 
 Hydrogen-bonding surfaces for ice mitigation patent thumbnailnew patent Hydrogen-bonding surfaces for ice mitigation
Various embodiments provide ice mitigating surface coatings and methods for applying ice mitigating surface coatings. Various embodiment ice mitigating surface coatings may be formed by hydrolysis of one or more substituted n-alkyldimethylalkoxysilanes terminated with functionalities having the following characteristics with respect to water: 1) non-polar interactions; 2) hydrogen bonding through donor and acceptor interactions; or 3) hydrogen bonding through acceptor interactions only.

06/23/16
20160177043 
 Anion exchange membrane for electrodialysis applications and process for the preparation thereof patent thumbnailnew patent Anion exchange membrane for electrodialysis applications and process for the preparation thereof
The present invention relates to the preparation of novel anion exchange membranes from bicomponent or tricomponent copolymers containing both quaternizable and cross-linkable moieties. The bicomponent copolymers consisted with polyacrylonitrile and poly(2-dimethylaminoethyl) methacrylate and the tricomponent copolymers consisted with polyacryloniterle and poly2-dimethylaminoethyl) methacrylate and polyn-butyl acrylate.

06/23/16
20160176891 
 Conformationally restricted 4-substituted-2,6-dimethylfuro[2,3-d]pyrimidines as multi-targeted receptor tyrosine kinase inhibitors and microtubule targeting antitumor agents patent thumbnailnew patent Conformationally restricted 4-substituted-2,6-dimethylfuro[2,3-d]pyrimidines as multi-targeted receptor tyrosine kinase inhibitors and microtubule targeting antitumor agents
Are provided. Pharmaceutical compositions comprising either the compound of formula i or formula ii are disclosed.

06/23/16
20160176776 
 Conversion of oxygenates to aromatics patent thumbnailnew patent Conversion of oxygenates to aromatics
Described herein are processes for production of hydrocarbon products comprising contacting a feed comprising methanol and/or dimethyl ether with a catalyst composition, which comprises a zeolite having a constraint index from 1-12 and an active binder comprising a metal oxide with a dehydrogenation function, under conditions sufficient to form the hydrocarbon product, wherein the hydrocarbon product comprises aromatics, olefins, and/or paraffins. Also described herein are catalyst compositions comprising a zeolite having a 10-/12-membered ring framework and a microporous surface area of at least 150 m2/g, and from ˜1 wt % to ˜10 wt % of a zinc oxide binder, the catalyst composition having a zinc to aluminum atomic ratio from ˜0.08 to ˜8.5..

06/23/16
20160175309 
 Polymorphs of arry-380, a selective her 2 inhibitor and pharmaceutical compositions containing them patent thumbnailnew patent Polymorphs of arry-380, a selective her 2 inhibitor and pharmaceutical compositions containing them
Polymorphs of n4-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-methylphenyl)-n6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine are provided herein. Processes for preparing the polymorphs and pharmaceutical composition comprising the polymorphs are also disclosed..

06/23/16
20160174556 
 Dermal compositions patent thumbnailnew patent Dermal compositions
Disclosed herein are veterinary compositions including imidacloprid or an analogue thereof; a pyrethroid; a solvent selected from the group consisting of n-methyl pyrrolidone, n-ethyl pyrrolidone and mixtures thereof; and dimethyl sulfoxide. The veterinary compositions of the invention are useful in methods of controlling parasites on or within warm-blooded domesticated animals..

06/16/16
20160172711 
 Electrolyte and lithium based batteries patent thumbnailElectrolyte and lithium based batteries
An example electrolyte includes a solvent mixture, a lithium salt, a non-polymerizing solid electrolyte interface (sei) precursor additive, and a solvent additive. The solvent mixture includes dimethyl carbonate (dmc) and fluoroethylene carbonate (fec) present in a volume to volume ratio ranging from 20 to 1 to 1 to 20.
Gm Global Technology Operations Llc


06/16/16
20160169098 
 Lubrication oil and internal-combustion engine fuel patent thumbnailLubrication oil and internal-combustion engine fuel
The lubrication oil is injected with lubrication oil impregnating agent composed of dimethylalkyl tertiary amine in the range from 0.01 to 1 volume % and desirably in the range from 0.1 to 0.5 volume %. Petroleum oil fuel is injected with fuel oil impregnating agent composed of dimethylalkyl tertiary amine in the range from 0.5 to 1 volume %.

06/16/16
20160168697 
 Delivery device, manufacturing system and process of manufacturing patent thumbnailDelivery device, manufacturing system and process of manufacturing
A delivery device, manufacturing system, and process of manufacturing are disclosed. The delivery device includes a feed tube and a chemical vapor deposition coating applied over an inner surface of the feed tube, the chemical vapor deposition coating being formed from decomposition of dimethylsilane.
Silcotek Corp.


06/16/16
20160168307 
 Method for producing polyoxymethylene dimethyl ethers from feedstock of concentrated formaldehyde patent thumbnailMethod for producing polyoxymethylene dimethyl ethers from feedstock of concentrated formaldehyde
The present invention pertains to the technical field of energy resource chemical industry, and in particular relates to a process for producing polyoxymethylene dimethyl ethers by directly using concentrated formaldehyde aqueous solution as feedstock to catalytically react with methanol and/or methylal in a fixed bed reactor. The method of the present invention uses concentrated formaldehyde aqueous solution with a concentration of over 80% by weight to react with methanol and/or methylal, in the presence of an acidic catalyst, to produce the required polyoxymethylene dimethyl ethers.
China University Of Petroleum (eastern China)


06/16/16
20160168182 

Method for the purification of decitabine


A method of preparing purified decitabine comprises mixing crude decitabine with solvent, such as dimethylacetamide, to form a solution or suspension and forming the purified decitabine from the solution or suspension. The forming step comprises adding an anti-solvent, such as ethanol, to the solution or suspension.
Johnson Matthey Public Limited Company


06/16/16
20160168109 

Method for producing n,n-dialkylhomofarnesic acid amide


Provided are: a method for producing n,n-dialkylhomofarnesic acid amide, which is a precursor of (±)-3a,6,6,9a-tetramethyldodecahydronaphtho[2.1-b]furan that is useful as a fragrance, at a high recovery rate of a raw material, at a high purity and at a high yield; and a method for producing (±)-3a,6,6,9a-tetramethyldodecahydronaphtho[2.1-b]furan. It is a method for producing n,n-dialkylhomofarnesic acid amide, said method including reacting nerolidol with n,n-dialkylformamide dimethyl acetal under the conditions that the n,n-dialkylformamide dimethyl acetal can be refluxed, wherein the molar ratio of the n,n-dialkylformamide dimethyl acetal to the nerolidol is in a range of 1.5 to 3..
Kao Corporation


06/16/16
20160168060 

Method for manufacturing methyl fluoride


An object of the present invention is to provide a method for producing methane fluoride that is useful, for example, as a dry etching gas, the method being more suitable for industrial production. To achieve this object, the present invention provides a method including reacting (a) dimethyl sulfate and (b) at least one fluorocompound in a liquid phase, the fluorocompound (b) being at least one compound selected from the group consisting of hydrogen fluoride and hydrofluoric acid salts, or a metal fluoride, wherein when the fluoride compound (b) includes hydrogen fluoride or a hydrofluoric acid salt, the reaction is carried out without a solvent or using a polar solvent as a solvent, and when the fluoride compound (b) is a metal fluoride, the reaction is carried out using water as a solvent..
Daikin Industries, Ltd.


06/09/16
20160160058 

Antimicrobial inks and sealants


Antimicrobial inks, sealants, coatings or varnishes that are manufactured in three distinct phases: phase 1, which is an oil phase comprising ethoxylate alcohol laureth 7, didecyldimethylammonium chloride, glutaric acid dialdehyde, pinus sylvestris, alkyldimemylberizylammonium chloride, parachlorometaxylenol, ethylenediaminetetraacetic acid, 2-hydroxypropanoic acid, hydroxy-9-cis-octadecenoic acid, cetyl alcohol wax, octadecenoic acid, palmityl alcohol, and epoxy-cis-9-octadecenoic acid; phase 2, which is a micro-emulsion phase comprising ethoxylate alcohol laureth-7, cetyl alcohol wax, pinus sylvestris, and propan-2-ol and phase 3, which combines the products of phases 1 and 2 with a base to produce the ink, sealant, coating or varnish.. .

06/09/16
20160158362 

Liquid bendamustine formulation


The present invention provides stable bendamustine-containing pharmaceutical compositions suitable for long term storage. The compositions include bendamustine, a pharmaceutically acceptable salt, and/or a hydrate form thereof, a solvent mixture of n,n-dimethylacetamide and glycerin, and an antioxidant.

06/02/16
20160157362 

Coating metal foil with n-heterocyclic carbene compounds containing organic functionalities for improving metal-to-resin adhesion


A carbene-coated metal foil is produced by applying an n-heterocyclic carbene (nhc) compound to one or more surfaces of a metal foil (e.g., an electrodeposited copper foil having a surface that is smooth and non-oxidized). The nhc compound contains a matrix-reactive pendant group that includes at least one of a vinyl-, allyl-, acrylic-, methacrylic-, styrenic-, amine-, amide- and epoxy-containing moiety capable of reacting with a base polymer (e.g., a vinyl-containing resin such as a polyphenylene oxide/triallyl-isocyanurate (ppo/taic) composition).
International Business Machines Corporation


06/02/16
20160157361 

Coating metal foil with n-heterocyclic carbene compounds containing organic functionalities for improving metal-to-resin adhesion


A carbene-coated metal foil is produced by applying an n-heterocyclic carbene (nhc) compound to one or more surfaces of a metal foil (e.g., an electrodeposited copper foil having a surface that is smooth and non-oxidized). The nhc compound contains a matrix-reactive pendant group that includes at least one of a vinyl-, allyl-, acrylic-, methacrylic-, styrenic-, amine-, amide- and epoxy-containing moiety capable of reacting with a base polymer (e.g., a vinyl-containing resin such as a polyphenylene oxide/triallyl-isocyanurate (ppo/taic) composition).
International Business Machines Corporation


06/02/16
20160155867 

Coating solution for forming light-absorbing layer, and producing coating solution for forming light-absorbing layer


A method of forming a coating solution for forming a light-absorbing layer of a solar cell, including dissolving a chalcogen and at least one metal or metal compound in dimethylsulfoxide and/or water in the presence of hydrazine to obtain a homogeneous hydrazine-coordinated metal chalcogenide complex solution; and adding at least one alcohol having 1 to 5 carbon atoms to the homogeneous hydrazine-coordinated metal chalcogenide complex solution.. .
Tokyo Ohka Kogyo Co., Ltd.


06/02/16
20160154328 

Electrophotographic photosensitive member, process cartridge and electrophotographic apparatus


To provide an electrophotographic photosensitive member that can allow a high-quality image, in which photomemory after repeated use in a high-speed process is suppressed, to be output, as well as a process cartridge and an electrophotographic apparatus including the electrophotographic photosensitive member. An electrophotographic photosensitive member wherein a charge generating layer includes a gallium phthalocyanine crystal in which an organic compound is contained, wherein the organic compound is at least one compound selected from the group consisting of dimethylsulfoxide, n,n-dimethylformamide, n-methylformamide, n-propylformamide, n-vinylformamide and n-methylpyrrolidone, the content of the organic compound is 0.1% by mass or more and 2.0% by mass or less based on a gallium phthalocyanine in the gallium phthalocyanine crystal, and a charge transporting layer includes a polycarbonate resin having structural units represented by the following formula (1)..
Canon Kabushiki Kaisha


06/02/16
20160154326 

Electrophotographic photosensitive member, producing electrophotographic photosensitive member, process cartridge and electrophotographic apparatus


The charge generating layer includes a gallium phthalocyanine crystal in which an organic compound (p) is contained, the organic compound (p) is at least one compound selected from the group consisting of dimethylsulfoxide, n,n-dimethylformamide, n-methylformamide, n-propylformamide, n-vinylformamide and n-methylpyrrolidone, the content of the organic compound (p) is 0.1% by mass or more and 1.5% by mass or less based on a gallium phthalocyanine in the gallium phthalocyanine crystal, and the charge transporting layer includes a resin having a siloxane structure, and a compound (q) having a boiling point of 150° c. Or more at 1 atm..
Canon Kabushiki Kaisha


06/02/16
20160152899 

Production of dimethyl ether


The present invention concerns the production and use of feedstock streams. Specifically, the present invention provides a process for the production of a commodity using two or more feedstock streams.

06/02/16
20160152537 

Systems and methods for manufacture of dimethyl ether (dme) from natural gas and flare gas feedstock


A unique design for a mobile system that reforms flare gas or natural gas, using air without steam, to directly produce dimethyl ether (dme), a diesel substitute, is disclosed. The system first reforms the air-methane mixture at ambient atmospheric pressures, and then compresses the resulting co-hydrogen-nitrogen gas mixture to up to 600 psi, and feeds it through a combined reactor which reacts the gas mixture directly into dimethyl ether.
Pioneer Energy Inc.


06/02/16
20160151309 

Prolonged release pharmaceutical composition containing 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol


A pharmaceutical formulation for prolonged release of the active ingredient 3-(3-dimethylamino-1-ethyl-2-methylpropyl)phenol or a pharmaceutically acceptable salt thereof in a matrix containing between 1 and 80 wt % of at least one pharmaceutically acceptable hydrophilic or hydrophobic polymer as a matrix forming agent and exhibiting in vivo the following release rate: 3 to 35% by weight (based on 100% by weight active ingredient) 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol released after 0.5 hours; 5 to 50% by weight 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol released after 1 hour; 10 to 75% by weight 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol released after 2 hours; 15 to 82% by weight 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol released after 3 hours; 30 to 97% by weight 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol released after 6 hours; more than 50% by weight 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol released after 12 hours; more than 70% by weight 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol released after 18 hours, and more than 80% by weight 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol released after 24 hours.. .
Gruenenthal Gmbh


06/02/16
20160150791 

Synergistic antimicrobial composition


A synergistic antimicrobial composition having two components. The first component is a hydroxymethyl-substituted phosphorus compound.
Dow Global Technologies Llc


05/26/16
20160148802 

Liquid chemical for forming protecting film


Disclosed is a liquid chemical for forming a water-repellent protecting film at least on a surface of a recessed portion of an uneven pattern at the time of cleaning a wafer having a finely uneven pattern at its surface and containing silicon at at least a part of the uneven pattern. This liquid chemical contains a silicon compound a represented by the general formula: r1asi(h)bx4-a-b and an acid a, the acid a being at least one selected from the group consisting of trimethylsilyl trifluoroactate, trimethylsilyl trifluoromethanesulfonate, dimethylsilyl trifluoroactate, dimethylsilyl trifluoromethanesulfonate, butyldimethylsilyl trifluoroactate, butyldimethylsilyl trifluoromethanesulfonate, hexyldimethylsilyl trifluoroacetate, hexyldimethylsilyl trifluoromethanesulfonate, octyldimethylsilyl trifluoroactate, octyldimethylsilyl trifluoromethanesulfonate, decyldimethylsilyl trifluoroacetate and decyldimethylsilyl trifluoromethanesulfonate..
Central Glass Company, Limited


05/26/16
20160146105 

Method and device for converting municipal waste into energy


A method and device for converting municipal waste into energy. This method involves heating the waste in multiple sections of a chamber to produce syngas and biochar.

05/26/16
20160145224 

Process for the preparation of an antidepressant and the intermediates thereof


The present invention relates to a process for the preparation of 1-[2-(2,4-dimethylphenylsulphanyl)phenyl]piperazine of formula (i), also known as vortioxetine, salts thereof, and intermediates useful for its synthesis.. .
Dipharma Francis S.r.l.


05/26/16
20160144058 

Ir dyes for fluorescence imaging


A method for organ imaging, comprising: administering to a subject a diagnostic effective amount of 2-((e)-2-((e)-3-(2-((e)-3,3-dimethyl-5-sulfonato-1-(4-sulfonatobutyl)indolin-2-ylidene)ethylidene)-2-phenoxycyclohex-1-en-1-yl)vinyl)-3,3-dimethyl-1-(4-sulfonatobutyl)-3h-indol-1-ium-5-sulfonate or 2-((e)-2-((e)-3-(2-((e)-3,3-dimethyl-5-sulfonato-1-(4-sulfonatobutyl)indolin-2-ylidene)ethylidene)-2-(4-sulfonatophenoxy)cyclohex-1-en-1-yl)vinyl)-3,3-dimethyl-1-(4-sulfonatobutyl)-3h-indol-1-ium-5-sulfonate. In one embodiment, the organ includes one or more of kidney, bladder, liver, gall bladder, spleen, intestine, heart, lungs and muscle..
Ll-cor, Inc.


05/26/16
20160143913 

Combination


The present invention relates to a method of treating cancer in a human and to pharmaceutical combinations useful in such treatment. In particular, the method relates to a cancer treatment method that includes administering n-{3-[3-cyclopropyl-5-(2-fluoro-4-iodo-phenylamino)-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydro-2h-pyrido[4,3-d]pyrimidin-1-yl]phenyl}acetamide, or a pharmaceutically acceptable salt or solvate thereof, and n-{(1s)-2-amino-1-[(3-fluorophenyl)methyl]ethyl}-5-chloro-4-(4-chloro-1-methyl-1h-pyrazol-5-yl)-2-thiophenecarboxamide, or a pharmaceutically acceptable salt thereof, to a human in need thereof..
Novartis Ag


05/26/16
20160143883 

Method of treating thrombocytopenia


Invented is a method of treating thrombocytopenia in a human in need thereof which comprises the administration of a therapeutically effective amount of a 3′-{n′-[1-(3,4-dimethylphenyl)-3-methyl-5-oxo-1,5-dihydropyrazol-4-ylidene]hydrazino}-2′-hydroxybiphenyl-3-carboxylic acid to such human.. .
Novartis Ag


05/26/16
20160143820 

Colorful gel and preparation method thereof


The present invention provides a colorful gel, comprising following components by weight percentage: 20.0% to 25.0% by weight of glycerin, 20.0% to 25.0% by weight of propylene glycol, 1.0% by weight of sea algae extract, 0.05% by weight of disodium edta, 0.06% by weight of allantoin, 0.05% by weight of sodium hyaluronate, 20.0% to 30.0% by weight of cyclopentasiloxane, 5.0 to 10.0% by weight of dimethicone, 0.5 to 1.0% by weight of sodium acrylate/sodium acryloyldimethyl taurate copolymer, 0.25 to 0.5% by weight of isohexadecane, 0.2% to 0.4% by weight of polysorbate-80, 1.5% by weight of soluble collagen, 0.5% by weight of caprylyl glycol, and water as the rest. The present invention also provides a preparation method of the colorful gel.
Guangzhou Sheencolor Cosmetics Co., Ltd.


05/19/16
20160137894 

Non-azeotropic fluid mixture for air conditioning devices


The composition of the mixture contains at least one polymerisation inhibitor agent (hydroquinone, benzotriazole, dimethyl-t-butylphenol).. .

05/19/16
20160137844 

Carbazole dioxazine pigment and a its preparation


The pigment is synthesized from 3-nitro-n-ethylcarbazole. The first step is nitration of 3-nitro-n-ethylcarbazole to form 3,6-dinitro-n-ethylcarbazole which is reduced to form 3-amino-6-nitro-n-ethylcarbazole.

05/19/16
20160137683 

Method for preparing epirubicin and intermediate thereof


The present invention provides a method for preparing epirubicin and an intermediate adaptive to the method. The preparation method may include: reacting tert-butyldimethylsilyl chloride with n-trifluoroacetyl adriamycin to obtain a first compound n-trifluoroacetyl-14-o-tert-butyldimethylsilyl adriamycin; oxidizing the first compound to obtain a second compound 4′-ketone-n-trifluoroacetyl-14-o-tert-butyldimethylsilyladriamycin; reducing the second compound to obtain a third compound n-trifluoroacetyl-14-o-tert-butyldimethylsilyl epirubicin; and performing deprotection and hydrolysis reactions on the third compound to obtain epirubicin.
Zhejiang Hisun Pharmaceutical Co., Ltd.


05/19/16
20160137589 

Use of 4-[ethyl(dimethyl)ammonio]butanoate in the treatment of cardiovascular disease


New compound 4-[ethyl(dimethyl)ammonio]butanoate, method of preparation thereof and use in the treatment of cardiovascular disease.. .
Jsc Grindeks


05/19/16
20160137587 

Transition-metal-free n-arylation of tertiary amines using arynes


The present invention relates to transition-metal-free process for the synthesis of tertiary arylamines comprises coupling reaction between arynes and n,n-dimethyl aniline compounds in presence of 18-crown-6, kf and thf.. .
Council Of Scientific & Industrial Research


05/19/16
20160136280 

Stable intravenous formulation


A stable lyophilized formulation for intravenous administration of the compound 4-{[(2r, 3s, 55)-4-(4-chloro-2-fluoro-phenyl)-3-(3-chloro-2-fluoro-phenyl)-4-cyano-5-(2,2-dimethyl-propyl)- pyrrolidine-2-carbonyl]-amino}-3-methoxy-benzoic acid 1-[2-(2-methoxy-ethoxy)-ethoxycarbonyloxy]-ethyl ester is provided.. .
Hoffmann-la Roche Inc.


05/19/16
20160135477 

Ready-to-drink tea beverages with reduced benzene and methods for making same


A ready-to-drink tea beverage contains tea extract, aerated water and benzoate, such as a benzoic acid salt. The beverage and/or the aerated water can contain at least 5.0 ppm dioxygen (o2) and preferably at least about 5.0 ppm o2.

05/12/16
20160133672 

Hybrid perovskite with adjustable bandgap


A method is provided for preparing a thin film of perovskite material having an adjustable bandgap. The method forms a thin film of material having the formula bx2, where anionic part x is a halide, and where the cation b is lead (pb), tin (sn), or germanium (ge).
Sharp Laboratories Of America, Inc.


05/12/16
20160131985 

Electrophotographic photosensitive member, process cartridge, and electrophotographic apparatus


Provided is an electrophotographic photosensitive member, including in the following order: a support; a charge-generating layer; and a charge-transporting layer, in which: the charge-generating layer includes a gallium phthalocyanine crystal in which an organic compound is contained; the organic compound is at least one compound selected from the group consisting of dimethyl sulfoxide, n,n-dimethylformamide, n-methylformamide, n-propylformamide, n-vinylformamide, and n-methylpyrrolidone; a content of the organic compound is 0.1% by mass or more and 1.5% by mass or less with respect to a mass of gallium phthalocyanine in the gallium phthalocyanine crystal; and the charge-transporting layer comprises at least one compound selected from the group consisting of a compound represented by the formula (1), a compound represented by the formula (2), a compound represented by the formula (3), and a compound represented by the formula (4).. .
Canon Kabushiki Kaisha


05/12/16
20160131658 

Method and kit for assessing viable cells


The present invention provides simple, rapid methods and procedures for analyzing cells, hereunder quantitative and qualitative assessment of cells, such as viability. The present invention relates to the use of various optionally substituted reporter compounds particularly detectable upon their reaction with thiol-containing species present in higher concentrations in intact (e.g., living) cells than in non-intact (e.g., dead, stressed and apoptotic) cells.
Chemometec A/s


05/12/16
20160130272 

Crystalline forms of n,n-dicyclopropyl-4-(1,5-dimethyl-1h-pyrazol-3-ylamino)-6-ethyl-1-methyl-1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridine-7-carboximide for the treatment of myeloproliferative disorders


Crystalline form, form n-2, of n,ndicyclopropyl-4-(1,5-dimethyl-1hpyrazol-3-ylamino)-6-ethyl-1-methyl-1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridine-7-carboxamide (compound i) is provided. Also provided are a pharmaceutical composition and an oral dosage form comprising form n-2 of compound i as well as a method of using the form n-2 of compound i in the treatment of myeloproliferative disorders, which include polycythaemia vera, thrombocythaemia and primary myelofibrosis..
Bristol-myers Squibb Company


05/12/16
20160129031 

Pyrazole derivative and use thereof for medical purposes


The present invention provides pyrazole derivatives, uses thereof for medical purposes and so on. More particularly, the present invention relates to pharmaceuticals useful for the prevention or treatment of constipation, which comprise as an active ingredient 3-(3-{4-[3-(β-d-glucopyranosyloxy)-5-isopropyl-1h-pyrazol-4-ylmethyl]-3-methylphenoxy}propylamino)-2,2-dimethylpropionamide, or a pharmaceutically acceptable salt thereof.
Kissei Pharmaceutical Co., Ltd.


05/12/16
20160129009 

High purity diaminophenothiazinium compounds including methylthioninium chloride (mtc)


This invention pertains generally to the field of chemical synthesis and purification, and more specifically to methods of synthesizing and purifying certain 3,7 diamino-phenothiazin-5-ium compounds (referred to herein as “diaminophenothiaziniumcompounds”) including methythioninium chloride (mtc) (also known as methylene blue). In one embodiment, the method comprises the steps of, in order: nitrosylation (nos); nitrosyl reduction (nr); thiosulfonic acid formation (tsaf); oxidative coupling (oc); cr(vi) reduction (cr); isolation and purification of zwitterionic intermediate (iapozi); ring closure (rc); chloride salt-formation (csf); one of: sulphide treatment (st); dimethyldithiocarbamate treatment (dt); carbonate treatment (ct); ethylenediaminetetraacetic acid treatment (edtat); organic extraction (oe); and recrystallisation (rx).
Wista Laboratories Ltd.


05/12/16
20160129003 

Pharmaceutical combinations


A pharmaceutical combination comprising: (a) a phosphatidylinositol-3-kinase inhibitor selected from 2-methyl-2-[4-(3-methyl-2-oxo-8-quinolin-3-yl-2,3-dihydro-imidazo[4,5-c]quinolin-1-yl)-phenyl]-propionitrile, 5-(2,6-di-morpholin-4-yl-pyrimidin-4-yl)-4-trifluoromethyl-pyridin-2-ylamine, (s)-pyrrolidine-1,2-dicarboxylic acid 2-amide 1-({4-methyl-5-[2-(2,2,2-trifluoro-1,1-dimethyl-ethyl)-pyridin-4-yl]-thiazol-2-yl}-amide) or any pharmaceutically acceptable salt thereof, and (b) an anaplastic lymphoma kinase inhibitor, particularly for use in the treatment or prevention of a proliferative disease; uses of such a combination in the treatment or prevention of proliferative diseases; to pharmaceutical compositions of the combination of said therapeutic agents and methods of treating a proliferative disease in a subject comprising administering to said subject a therapeutically effective amount of such a combination.. .
Novartis Ag


05/12/16
20160128952 

Pharmaceutical combination


A combination comprising as components (a) the compound 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol, and (b) paracetamol or a derivative thereof, a pharmaceutical formulation and a dosage form comprising said combination as well as a method of treating pain, e.g. Chronic or acute pain, characterized in that components (a) and (b) are administered simultaneously or sequentially to a mammal, wherein component (a) may be administered before or after component (b) and wherein components (a) or (b) are administered to the mammal either via the same or a different pathway of administration..
Gruenenthal Gmbh


05/05/16
20160124329 

Electrophotographic photosensitive member, process cartridge and electrophotographic apparatus, and chlorogallium phthalocyanine crystal and producing the same


An electrophotographic photosensitive member includes a support and a photosensitive layer in this order. The photosensitive layer contains a chlorogallium phthalocyanine crystal represented by formula (1) in which at least one organic compound selected from n,n-dimethylformamide and dimethyl sulfoxide is contained.
Canon Kabushiki Kaisha


05/05/16
20160124328 

Electrophotographic photosensitive member, process cartridge and electrophotographic apparatus


An electrophotographic photosensitive member wherein a charge generating layer of the electrophotographic photosensitive member includes a gallium phthalocyanine crystal in which an organic compound is contained, wherein the organic compound is at least one compound selected from the group consisting of dimethylsulfoxide, n,n-dimethylformamide, n-methylformamide, n-propylformamide, n-vinylformamide and n-methylpyrrolidone, the content of the organic compound is 0.1% by mass or more and 2.0% by mass or less based on a gallium phthalocyanine in the gallium phthalocyanine crystal, and a charge transporting layer of the electrophotographic photosensitive member includes a polycarbonate resin having structural units represented by formulae (1) and (2).. .
Canon Kabushiki Kaisha


05/05/16
20160122938 

Chemically stable, stain-, abrasion- and temperature-resistant, easy-to-clean metalware for use in elevated temperatures


A metalware for use in elevated temperatures, where the surface of the said ware is coated with a layer which is a hydrolysis and polycondensation product of a composition comprising tetraethoxy silane (teos), methyl trimethoxy silane (mtms), dimethyl siloxane (dms), inorganic filler and polar solvent where the said composition comprises 1,3-dialkyl imidazolium alkyl sulfate.. .
Eksen Makine Sanayi Ve Ticaret A.s.


05/05/16
20160122375 

Immobilized metathesis tungsten catalysts and use thereof in olefin metathesis


Compound of formula (i) wherein m is w; r1 is h, aryl, heteroaryl, alkyl, or heteroalkyl, optionally substituted, respectively; r2 and r3 can be the same or different and are alkyl, alkenyl, heteroalkyl, heteroalkenyl, aryl, or heteroaryl, optionally substituted, respectively, or hydrogen; r5 is a residue r6—x—, wherein r6 is alkyl, aryl, heteroalkyl, heteroaryl, optionally substituted, respectively; (r7, r8, r9)si; wherein r7, r8, r9 are independently alkyl, alkoxy, phenyl or phenoxy, optionally substituted, respectively; (r10, r11, r12)c, wherein r10, r11, r12 are independently phenyl, alkyl, optionally substituted, respectively; x═o, s, or nr13, wherein r13 is h; or alkyl or aryl, optionally substituted, respectively; or r5 is r6—co—nr13, wherein r6 and nr13 have the meaning as defined above, or wherein r6 and r13 taken together form a carbon chain having from 2 to 6 carbon atoms; r5 is a 4 to 8 membered n-containing carbon ring, wherein n is linked to m; and r4 is a residue o—si(o—)3, and represents silica to which m is linked forming a m-o—si(o—)3 moiety, preferably wherein silica is comprised in a solid support; under the proviso that a compound in which r1=2,6-diisopropylphenyl, r5 dimethylpyrrol-1-yl, r2=tbu, and r3═h is excluded.. .
Ximo Ag


05/05/16
20160122287 

Crystalline forms of (-)-(1r,2r)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride


A hitherto unknown crystalline form of (−)-(1r,2r)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride, pharmaceutical compositions containing the new crystalline form, methods of producing the new crystalline form, and a related method of use including treatment of, e.g., pain and/or urinary incontinence.. .
Gruenenthal Gmbh


05/05/16
20160122277 

Process of production of dehydrolinalyl acetate (ii)


The present invention is related to a novel and improved process for the production of dehydrolinalyl acetate (dla), which 1upac name is acetic acid 1-ethynyl-1,5-dimethyl-hex-4-enyl ester, starting from dehydrolinalool (dll), which 1upac name is 3,7-dimethyloct-6-en-1-yn-3-ol, by acetylation.. .
Dsm Ip Assets B.v.


05/05/16
20160120988 

Pazopanib formulation


A granulation formulation of 5-[[4-[(2,3-dimethyl-2h-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methylbenzenesulfonamide or pharmaceutically acceptable salt thereof, which is adapted for reconstitution with an aqueous vehicle, and associated oral suspension.. .
Novartis Ag


05/05/16
20160120937 

Pharmaceutical compositions comprising 8-substituted dibenzylbutyrolactone lignans


Therapeutic compositions comprising at least one 8-substituted-dibenzylbutyrolactone lignan, preferably a lignan is selected from the group of nortrachelogenin, diasteromeric forms of nortrachelogenin, isomeric forms of nortrachelogenin and combinations thereof as well as 8-methylmatairesinol and 8-methyldimethylmatairesinol, for use in a method of treating cancer or a similar condition wherein the growth factor signaling pathway of a mammal is deregulated. The invention also provides therapeutic pharmaceutical combinations comprising a hydroxy-dibenzylbutyrolactone lignan and at least one trail receptor agonist.

05/05/16
20160120871 

Pharmaceutical combinations of a pi3k inhibitor and a microtubule destabilizing agent


The present invention relates to a combination comprising (a) a phosphatidylinositol 3-kinase inhibitor selected from 5-(2,6-di-morpholin-4-yl-pyrimidin-4-yl)-4-trifluoromethyl-pyridin-2-ylamine, (s)-pyrrolidine-1,2-dicarboxylic acid 2-amide 1-({4-methyl-5-[2-(2,2,2-trifluoro-1,1-dimethyl-ethyl)-pyridin-4-yl]-thiazol-2-yl}-amide) or a pharmaceutically acceptable salts thereof, and (b) a microtubule destabilizing agent for simultaneous, separate or sequential use for the treatment of a tumor disease; a pharmaceutical composition comprising such combination; a method of treating a subject having a tumor disease comprising administration of said combination to a subject in need thereof; use of such combination for preparation of a medicament for the treatment of a tumor disease; and a commercial package thereto.. .
Novartis Ag


05/05/16
20160120177 

Agrochemical formulations


A liquid herbicide composition is provided comprising at least an electrolytic agrochemical active; at least an alkyl n,n-dimethylamine n-oxide, and at least one (c9-c20) alkyl sulfosuccinic acid mono ester salt.. .
Upl Limited


04/28/16
20160115405 

Organic fuel and waste reformer


This invention pertains to the non-catalytic oxygenated steam reforming of organic matter to produce a gas mixture rich in hydrogen, carbon monoxide and carbon dioxide. The reforming gas is used for production of methane, methanol, dimethyl ether, oxygen, carbon dioxide, and other compounds via downstream processing catalytic gas-phase processes and electrolysis.
Pioneer Astronautics


04/28/16
20160115165 

Crystalline form of n,n-dicyclopropyl-4-(1,5-dimethyl-1h-pyrazol-3-ylamino)-6-ethyl-1-methyl-1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridine-7-carboxamide for the treatment of myeloproliferative disorders


Crystalline form, form hi.5-4, of n,n-di-cyclopropyl-4-(1,5-dimethyl-1h-pyrazol-3-ylamino)-6-ethyl-1-methyl-1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridine-7-carboxamide, (compound i) is provided. Also provided are a pharmaceutical composition and an oral dosage form comprising form hi.5-4 of compound i as well as a method of using the form hi.5-4 of compound i in the treatment of myeloproliferative disorders, which include polycythaemia vera, thrombocythaemia and primary myelofibrosis..
Bristol-myers Squibb Company


04/28/16
20160115113 

Aerobic oxidative esterification of sugar-derived 1,4-disubstituted benzene for direct synthesis of dimethylterephthalate


This invention relates to a dimethylterephthalate production process comprising reacting substituted furan with ethylene under cycloaddition reaction conditions and in the presence of a cycloaddition catalyst to produce a bicyclic ether, dehydrating the bicyclic ether to produce a substituted phenyl, dissolving said substituted phenyl in methanol, and oxidizing and esterifying the substituted phenyl in the presence of an oxidative esterification catalyst to form dimethylterephthalate. Importantly, the process does not include oxidizing the substituted phenyl to form terephthalic acid..
Exxonmobil Chemical Patents Inc.


04/28/16
20160115038 

Method for making molecular sieve ssz-102


A method for making a new crystalline molecular sieve designated ssz-102 is disclosed using an n,n′-dimethyl-1,4-diazabicyclo[2.2.2]octane dication as a structure directing agent. Ssz-102 has esv framework topology..
Chevron U.s.a. Inc


04/28/16
20160115037 

Molecular sieve ssz-102


A new crystalline molecular sieve designated ssz-102 having esv framework topology is disclosed. Ssz-102 is synthesized using an n,n′-dimethyl-1,4-diazabicyclo[2.2.2]octane dication as a structure directing agent..
Chevron U.s.a. Inc


04/28/16
20160114313 

Processes using molecular sieve ssz-102


Uses are disclosed for a new crystalline molecular sieve designated ssz-102 synthesized using an n,n′-dimethyl-1,4-diazabicyclo[2.2.2]octane dication as a structure directing agent. Ssz-102 has esv framework topology..
Chevron U.s.a. Inc


04/28/16
20160113275 

Tobacco axillary bud growth inhibitor and inhibiting tobacco axillary bud growth


An inhibitor for tobacco axillary bud growth, containing chlorthal-dimethyl and aliphatic alcohol selected from decyl alcohol, 2-ethyl hexanol and geraniol in combination; and a method for inhibiting tobacco axillary bud growth, which includes applying the inhibitor for tobacco axillary bud growth.. .
Sds Biotech K. K.


04/21/16
20160111276 

Vapor deposition of metal oxides, silicates and phosphates, and silicon dioxide


Metal silicates or phosphates are deposited on a heated substrate by the reaction of vapors of alkoxysilanols or alkylphosphates along with reactive metal amides, alkyls or alkoxides. For example, vapors of tris(tert-butoxy)silanol react with vapors of tetrakis(ethylmethylamido)hafnium to deposit hafnium silicate on surfaces heated to 300° c.

04/21/16
20160111272 

Vapor deposition of silicon-containing films using penta-substituted disilanes


Disclosed are methods of depositing silicon-containing films on one or more substrates via vapor deposition processes using penta-substituted disilanes, such as pentahalodisilane or pentakis(dimethylamino)disilane.. .

04/21/16
20160108163 

Polylactic acid (pla) with low moisture vapor transmission rates by grafting through of hydrophobic polymers directly to pla backbone


Polylactic acid-backbone graft and bottlebrush copolymers with low moisture vapor transmission rates are synthesized by polymerizing a lactide-functionalized hydrophobic macromonomer using ring-opening polymerization (rop). In some embodiments of the present invention, the macromonomer is a lactide-functionalized hydrophobic polymer that may be synthesized by, for example, polymerizing a hydrophobic monomer (e.g., a fluorinated vinyl monomer such as 2,2,2-trifluroethyl methacrylate) capable of undergoing radical polymerization (e.g., styrenic, vinylic, acrylic, etc.) using a brominated lactide initiator via atom transfer radical polymerization (atrp).

04/21/16
20160107990 

4-(5-(4-chlorophenyl)-2-(2-cyclopropylacetyl)-1,4-dimethyl-1h-pyrrol-3-yl)benzenesulfonamide as alpha 7 nachr modulator


Disclosed are an alpha 7 nachr receptor modulator compound, 4-(5-(4-chlorophenyl)-2-(2-cyclopropylacetyl)-1,4-dimethyl-1h-pyrrol-3-yljbenzenesulfonamide, its tautomeric form, its pharmaceutically acceptable salts, pharmaceutical compositions comprising the compound or a salt thereof, and a method of treating various diseases, disorders or conditions, for example, alzheimer's disease, mild cognitive impairment, senile dementia, vascular dementia, dementia of parkinson's disease, and attention deficit disorder.. .

04/21/16
20160107134 

Amphoteric ester sulfonates


Disclosed are a variety of amphoteric ester sulfonates, including 3-(n,n-dimethyl-cocoylpropylammonio-1-yl)-2-hydroxypropanesulfonate. These amphoteric ester sulfonates can be advantageously prepared in high yield and purity by a two-step chemoenzymatic process, and have excellent surfactant properties..

04/21/16
20160106835 

Combination therapies for cancer


A novel combination comprising a b-raf inhibitor, particularly n-{3-[5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamide or a pharmaceutically acceptable salt thereof, the mek inhibitor n-{3-[3-cyclopropyl-5-(2-fluoro-4-iodo-phenylamino)6,8-dimethyl; -2,4,7-trioxo-3,4,6,7-tetrahydro-2h-pyrido[4,3-d]pyrimidin-1-yl]phenyl}acetamide, or a pharmaceutically acceptable salt or solvate thereof, and a pd-1 antagonist; pharmaceutical compositions comprising the same and methods of using such combinations and compositions in the treatment of conditions in which the inhibition of mek and/or b-raf and/or immune modulation through pd-1 is beneficial, e.g., cancer.. .

04/21/16
20160106641 

Stable compositions for whitening teeth and methods of using same


A thickened tooth whitening composition in gel form comprises hydrogen peroxide or a hydrogen peroxide precursor, and a thickening polymer or copolymer comprising a pendant sulfonic acid group moiety, preferably hydroxyethyl acrylate/sodium acryloyldimethyltaurate copolymer. Gels in accordance with the invention exhibit an extended shelf life without requiring refrigeration or other special storage conditions.

04/14/16
20160102300 

Immobilized proline-specific endoprotease


The present invention relates to immobilized proline-specific endoprotease, wherein the proline-specific endoprotease is immobilized on a carrier comprising methacrylate which has been functionalized with amino dimethylene, and wherein the carrier has a particle size range of 100 to 400 μm. The invention also relates to a process for producing beer comprising the steps of preparing a mash, fermenting the beer, and stabilizing the beer, wherein the beer is incubated with the immobilized proline-specific endoprotease..

04/14/16
20160102191 

Silicone rubber composition and manufacturing method thereof


Disclosed are a silicone rubber composition and a preparation method thereof. The silicone rubber composition comprises a polydimethylvinylsiloxane, a silica filler, a polymethylvinylsiloxane oil, a hydrogen-modified polyorganosiloxane, a platinum-based catalyst, and a polymethylhydrogensiloxane vulcanizing agent..

04/14/16
20160102085 

Novel (cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles


This invention relates to novel (cyano-dimethyl-methyl)-isoxazolesand-[1,3,4]thiadiazoles and their use as cb2 cannabinoid receptor agonists, pharmaceutical compositions containing the same, and their use for the treatment of cb2 receptor mediated disorders or conditions.. .

04/14/16
20160102048 

N-(4-(bis(4-(dimethylamino)phenyl)methylene)-8-(dimethylamino)


This disclosure relates to n-(4-(bis(4-(dimethylamino)phenyl)methylene)-8-(dimethylamino)naphthalen-1(4h)-ylidene)-n-methylmethanaminium, derivatives, and uses related thereto. In certain embodiments, the disclosure relates to compounds of formula i.

04/14/16
20160102032 

Apparatus and process for producing gasoline, olefins and aromatics from oxygenates


Apparatuses and processes for converting an oxygenate feedstock, such as methanol and/or dimethyl ether, in a fluidized bed containing a catalyst to hydrocarbons, such as gasoline boiling components, olefins and aromatics are provided herein.. .

04/14/16
20160102031 

Apparatus and process for producing gasoline, olefins and aromatics from oxygenates


Apparatuses and processes for converting an oxygenate feedstock, such as methanol and dimethyl ether, in a fluidized bed containing a catalyst to hydrocarbons, such as gasoline boiling components, olefins and aromatics are provided herein.. .

04/14/16
20160101986 

Method for making euo framework type molecular sieves


A method for preparing euo framework type molecular sieve is disclosed using an n,n′-dimethyl-1,4-diazabicyclo[2.2.2]octane dication as a structure directing agent. The euo framework type molecular sieve, in its as-synthesized form, contains in its intracrystalline pores the n,n′-dimethyl-1,4-diazabicyclo[2.2.2]octane dication..

04/14/16
20160101062 

Treatment and prevention of cardiovascular disease and thrombosis


Provided herein are compositions for the treatment and/or prevention of cardiovascular disease (cvd), and methods of application and use thereof. In particular, the present invention provides treatment and/or prevention of cardiovascular disease with compounds that inhibit the production of tma in the gut, such as 3,3-dimethyl-1-butanol (dmb) or other compounds represented by formula i or as shown in figs.

04/07/16
20160097349 

Mixed fuel supply system for internal combustion engine, vehicle, and mixed fuel supply internal combustion engine


A mixed fuel supply system includes a dimethyl ether (“dme”) tank which stores dme, a dme supply path which supplies the dme and a light oil supply system. The dme supply path is connected to a transfer path between a feed pump and a fuel injection pump.
Isuzu Motors Limited


04/07/16
20160097015 

Bearing material


A plastic bearing material of a bearing may include a block copolymer. The block copolymer may include structural blocks of two or more different polymers.

04/07/16
20160096863 

Methods of preparing intermediate of fluticasone propionate


A method of preparing a thioic acid intermediate of fluticasone propionate includes: treating a 17β-[(n,n-dimethyl carbamoyl)thio]carbonyl compound in a solution including an alcohol and an alkali metal hydroxide, an alkaline-earth metal hydroxide, or a mixture thereof to cleave an amide from the 17β-[(n,n-dimethyl carbamoyl)thio]carbonyl compound; treating the solution to separate an aqueous portion; and adding an acid to the aqueous portion to obtain the thioic acid intermediate of fluticasone propionate. A method of preparing fluticasone propionate includes preparing the thioic acid intermediate of fluticasone propionate, and alkylating the thioic acid intermediate of fluticasone propionate to prepare the fluticasone propionate..
Amphastar Pharmaceuticals Inc.


04/07/16
20160096838 

Crystalline form of n,n-dicyclopropyl-4-(1,5-dimethyl-1h-pyrazol-3-ylamino)-6-ethyl-1-methyl-1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridine-7-carboxamide for the treatment of myeloproliferative disorders


Crystalline form, form t2h1.5-4, of n,ndicyclopropyl-4-(1,5-dimethyl-1 hpyrazol-3-ylamino)-6-ethyl-1-methyl-1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridine-7-carboxamide, (compound (i)) is provided. Also provided is a pharmaceutical composition and an oral dosage form comprising form t2h1.5-4 of compound (i) as well as a method of using the form t2h1.5-4 of compound (i) in the treatment of myeloproliferative disorders, which include polycythaemia vera, thrombocythaemia and primary myelofibrosis..
Bristol-myers Squibb Company


04/07/16
20160096816 

Method of preparing intermediate of salmeterol


A method of preparing an intermediate of salmeterol (compound 1, 2-amino-1-(2,2-dimethyl-4h-1,3-benzodioxin-6-yl)ethanol) includes: reacting compound 2 with 2-methoxypropene in a first organic solvent to produce a reaction solution including compound 3, compound 2 including a 2-bromo precursor of compound 1; reacting compound 3 with a nitrogen source to produce compound 4; reacting compound 4 with sodium borohydride in a second organic solvent to produce compound 5; and debenzylating compound 5 by ammonium formate/palladium-carbon catalytic transfer hydrogenation in a third organic solvent to produce compound 1. A method of preparing salmeterol includes preparing compound 1, and reacting compound 1 to prepare salmeterol..
Amphastar Pharmaceuticals Inc.


04/07/16
20160096807 

Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator


The present disclosure relates to co-crystals comprising n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide (compound 1) and a co-former and methods for their preparation. The present disclosure further relates to pharmaceutical compositions comprising the co-crystal forms, as well as methods of treatment therewith and kits..
Vertex Pharmaceuticals Incorporated




Dimethyl topics: Physiologic, Hydrochloric Acid, Fresnel Zone, Aberration, Ophthalmic, Liquid Crystal, Imaging System, Pharmaceutically Acceptable Salt, Pharmaceutically Acceptable Salts, Chloric Acid, Tartaric Acid, Fumaric Acid, Antagonist, Bradykinin, Enantiomer

Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Dimethyl for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Dimethyl with additional patents listed. Browse our RSS directory or Search for other possible listings.


0.6921

4602

0 - 1 - 102